Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

Siddhartha Devarakonda; Ramaswamy Govindan; Daniel Morgensztern

doi:10.1016/j.ccell.2020.07.011

Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer

Cancer Cell. 2020 Sep 14;38(3):320-322. doi: 10.1016/j.ccell.2020.07.011. Epub 2020 Aug 27.

Authors

Siddhartha Devarakonda¹, Ramaswamy Govindan¹, Daniel Morgensztern²

Affiliations

¹ Alvin Siteman Cancer Center at Washington University, Washington University School of Medicine, 660 S Euclid Box 8056, St. Louis, MO, USA.
² Alvin Siteman Cancer Center at Washington University, Washington University School of Medicine, 660 S Euclid Box 8056, St. Louis, MO, USA. Electronic address: Danielmorgensztern@wustl.edu.

PMID: 32857949
DOI: 10.1016/j.ccell.2020.07.011

Abstract

In a recent Nature article, Middleton et al. report the National Lung Matrix trial results where patients with previously treated non-small cell lung cancer (NSCLC) are assigned to personalized therapy based on the results of a 28-gene next-generation sequencing panel test.

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
High-Throughput Nucleotide Sequencing
Humans
Lung
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation